$GTBP News

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

Nasdaq Grants GT Biopharma Additional 180 Days To Regain Compliance

GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma Q4 EPS $(4.84) Down From $(1.66) YoY

GT Biopharma Reported FY25 Net Loss Of $28.4M, Cash Balance Of ~$9M To Fund Operations Through The Fourth Quarter Of 2026

GT Biopharma Receives FDA Clearance Of Investigational New Drug Application For GTB-5550 TriKE

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

EXCLUSIVE: GT Biopharma Announces IND Submission For GTB-5550 TriKE; Reports Preliminary Unaudited Cash Balance Of ~$7M As Of Dec. 31, 2025

Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

GT Biopharma Advances Potent NK-Cell Therapies As GTB 3650, Is Currently Being Tested In Phase 1 Trials For Patients With Relapsed Or Refractory Acute Myeloid Leukemia

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

GT Biopharma Completes Cohort 3 In GTB-3650 Formal Safety Review With No Safety Or Tolerability Issues Observed

GT Biopharma Completes Cohort 3 In GTB-3650 Formal Safety Review With No Safety Or Tolerability Issues Observed

GT Biopharma shares are trading higher after the company announced that enrollment in the dose escalation cohorts of the Phase 1 trial, evaluating GTB-3650 for the treatment of relapsed or refractory CD33 expressing hematologic malignancies, is on track.

EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers

EXCLUSIVE: GT Biopharma Tells Benzinga 'Upon successful completion of the Cohort 3 safety assessment, the trial will continue to dose escalate with initiation of Cohort 4 dosing planned by year-end 2025, and flexibility to dose up to 7 cohorts if necessary; additional data updates anticipated in Q1 2026'